Literature DB >> 26191362

Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.

Eeda Venkateswararao1, Min-Jeong Son1, Niti Sharma1, Manoj Manickam1, PullaReddy Boggu1, Young Ho Kim1, Sun-Hee Woo1, Sang-Hun Jung1.   

Abstract

Chrysosplenol C (4',5,6-trihydroxy-3,3',7-trimethoxyflavone) isolated from Miliusa balansae has unique structural features as a reversible inotropic agent independent of β-adrenergic signaling and with selective activation of cardiac myosin ATPase. Hence, a series of chrysosplenol analogues were synthesized and explored for identification of pharmacophore that is essential for the increasing contractility in rat ventricular myocytes. Analogue 7-chloro-2-(3-hydroxyphenyl)-3-methoxy-4H-chromen-4-one showed highly potent contractility (54.8% at 10 μM) through activating cardiac myosin ATPase (38.7% at 10 μM). Our systematic structure-activity relationship study revealed that flavonoid nucleus of chrososplenol C appears to be an essential basic skeleton and hydrophobic substituent at position 7 of chromenone such as methoxy or chloro enhances the activity. Additionally, our ATPase study suggested that these chrysosplenol analogues have selectivity toward cardiac myosin activation. Thus, the novel flavonone with 3-/7-hydrophobic substituent and 3'-hydrogen bonding donor function is a novel scaffold for discovery of a new positive inotropic agent.

Entities:  

Keywords:  Chrysosplenol C; contractility; myosin activation; positive inotrope

Year:  2015        PMID: 26191362      PMCID: PMC4499824          DOI: 10.1021/acsmedchemlett.5b00043

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

Review 1.  Inotropic therapy for heart failure: an evidence-based approach.

Authors:  G M Felker; C M O'Connor
Journal:  Am Heart J       Date:  2001-09       Impact factor: 4.749

2.  Heart failure with preserved left ventricular systolic function: a hospital cohort study.

Authors:  C Berry; K Hogg; J Norrie; K Stevenson; M Brett; J McMurray
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

3.  Length of stay and procedure utilization are the major determinants of hospital charges for heart failure.

Authors:  E F Philbin; P A McCullough; G W Dec; T G DiSalvo
Journal:  Clin Cardiol       Date:  2001-01       Impact factor: 2.882

4.  Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.

Authors:  Bradley P Morgan; Alexander Muci; Pu-Ping Lu; Xiangping Qian; Todd Tochimoto; Whitney W Smith; Marc Garard; Erica Kraynack; Scott Collibee; Ion Suehiro; Adam Tomasi; S Corey Valdez; Wenyue Wang; Hong Jiang; James Hartman; Hector M Rodriguez; Raja Kawas; Sheila Sylvester; Kathleen A Elias; Guillermo Godinez; Kenneth Lee; Robert Anderson; Sandra Sueoka; Donghong Xu; Zhengping Wang; Nebojsa Djordjevic; Fady I Malik; David J Morgans
Journal:  ACS Med Chem Lett       Date:  2010-08-20       Impact factor: 4.345

5.  Synthesis and aromatase inhibitory activity of flavanones.

Authors:  Christelle Pouget; Catherine Fagnere; Jean-Philippe Basly; Anne-Elise Besson; Yves Champavier; Gerard Habrioux; Albert-Jose Chulia
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

6.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.

Authors:  M J Lenzen; W J M Scholte op Reimer; E Boersma; P J M J Vantrimpont; F Follath; K Swedberg; J Cleland; M Komajda
Journal:  Eur Heart J       Date:  2004-07       Impact factor: 29.983

7.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

Authors:  V S Moiseyev; P Põder; N Andrejevs; M Y Ruda; A P Golikov; L B Lazebnik; Z D Kobalava; L A Lehtonen; T Laine; M S Nieminen; K I Lie
Journal:  Eur Heart J       Date:  2002-09       Impact factor: 29.983

8.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population.

Authors:  F D R Hobbs; J E Kenkre; A K Roalfe; R C Davis; R Hare; M K Davies
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

Review 10.  Novel cardiac myosin activators for acute heart failure.

Authors:  Thanjavur K M Bragadeesh; Gaurav Mathur; Andrew L Clark; John G F Cleland
Journal:  Expert Opin Investig Drugs       Date:  2007-10       Impact factor: 6.206

View more
  1 in total

Review 1.  Genus Miliusa: A Review of Phytochemistry and Pharmacology.

Authors:  Ninh The Son
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-14       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.